4921-87-3

Basic information

• Product Name: N-[(4-phenyl-1,3-thiazol-2-yl)carbamothioyl]benzamide
• Synonyms: benzamide, N-[[(4-phenyl-2-thiazolyl)amino]thioxomethyl]-; N-[(4-Phenyl-1,3-thiazol-2-yl)carbamothioyl]benzamide
• CAS NO: 4921-87-3
• Molecular Formula: C₁₇H₁₃N₃OS₂
• Molecular Weight: 339.4346
• Mol File: 4921-87-3.mol
• Article Data: 3

Chemical Properties

• Density: 1.376g/cm³
• Refractive Index: 1.72
• CAS DataBase Reference: N-[(4-phenyl-1,3-thiazol-2-yl)carbamothioyl]benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(4-phenyl-1,3-thiazol-2-yl)carbamothioyl]benzamide(4921-87-3)
• EPA Substance Registry System: N-[(4-phenyl-1,3-thiazol-2-yl)carbamothioyl]benzamide(4921-87-3)

Safety Data

• Hazardous Substances Data: 4921-87-3(Hazardous Substances Data)

Upstream product

• 2010-06-2 2-Amino-4-phenylthiazole 
• 532-55-8 Benzoyl isothiocyanate 
• 614-23-3 N-benzoylthiourea 
• 1147550-11-5 ammonium thiocyanate 
• 98-88-4 benzoyl chloride 

Downstream Products

• 7709-31-1 N'-(4-phenylthiazol-2-yl)thiourea 
• 113333-16-7 (4-Phenyl-thiazol-2-yl)-(4-p-tolyl-thiazol-2-yl)-amine 
• 113333-13-4 [4-(4-Chloro-phenyl)-thiazol-2-yl]-(4-phenyl-thiazol-2-yl)-amine 
• 113333-10-1 [4-(4-Bromo-phenyl)-thiazol-2-yl]-(4-phenyl-thiazol-2-yl)-amine 
• 89402-65-3 [4-Phenyl-2-(4-phenyl-thiazol-2-ylamino)-thiazol-5-yl]-acetic acid 
• 89402-66-4 [4-(4-Chloro-phenyl)-2-(4-phenyl-thiazol-2-ylamino)-thiazol-5-yl]-acetic acid 
• 89402-67-5 [4-(4-Methoxy-phenyl)-2-(4-phenyl-thiazol-2-ylamino)-thiazol-5-yl]-acetic acid 
• 78618-22-1 [Cu₂(C₆H₅C₃NSHNHCSNHCOC₆H₅)2Br₄] 
• 78618-21-0 [Cu₂(C₆H₅C₃NSHNHCSNHCOC₆H₅)2Cl₄] 
• 78618-27-6 [Co₂(C₆H₅C₃NSHNHCSNHCOC₆H₅)2(NO₃)4] 
• 78618-23-2 [Cu₂(C₆H₅C₃NSHNHCSNHCOC₆H₅)2(NO₃)4] 
• 78618-24-3 [Cu₂(C₆H₅C₃NSHNHCSNHCOC₆H₅)2(ClO₄)4] 
• 78618-26-5 [Co₂(C₆H₅C₃NSHNHCSNHCOC₆H₅)2Cl₄] 

Relevant articles and documents

GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS

The invention relates to guanidine compounds of general formula (I), corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and pharmaceutically acceptable salts thereof. The invention further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors in order to treat diseases modulated by 5-HT5 receptor activity, especially treat neurodegenerative and neuropsychiatric disorders and the signs, symptoms, and malfunctions associated therewith.

Synthesis and Antiinflammatory Activity of Some 5-Thiazoleacetic Acids

Four series of 5-thiazoleacetic acids (I, II, III and IV) have been synthesized for evaluation as potential antiinflammatory agents.Compounds of the series I, II and IV have been prepared by the condensation of various β-aroyl-β-bromopropionic acids (VIII